HS-20122 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 1. The lead sponsor is Hansoh BioMedical R&D Company. The most-studied condition is Advanced Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1 | Recruiting | Hansoh BioMedical R&D Company | China |
|
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
NCT07645222 · ClinicalTrials.gov ↗ · Lung Cancer
|
Phase 1 | Recruiting | Hansoh BioMedical R&D Company | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Hansoh BioMedical R&D Company | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name HS-20122 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Hansoh BioMedical R&D Company. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HS-20122 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HS-20122 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HS-20122 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.